Stockscreener 앱 받기
5.28
0.38%
-0.01
전일 마감가:
$5.27
열려 있는:
$5.1
하루 거래량:
90,869
Relative Volume:
0.18
시가총액:
$9.26M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+13.39%
1개월 성능:
+66.67%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.10
$5.41
1주일 범위
$4.25
$5.49
52주 변동 폭
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
명칭
Neuphoria Therapeutics Inc
전화
61 8 8150 7400
주소
200 GREENHILL ROAD, EASTWOOD SA
NEUP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
5.30 | 9.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.12 | 118.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.91 | 74.34B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
640.70 | 38.83B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.38 | 32.36B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.05 | 29.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | 재확인 | Maxim Group | Buy |
| 2022-01-10 | 개시 | Berenberg | Buy |
| 2022-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-01-10 | 개시 | Evercore ISI | Outperform |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Neuphoria Therapeutics Inc 주식(NEUP)의 최신 뉴스
Neuphoria Therapeutics Inc. (NEUP) reports earnings - Quartz
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes - MSN
Neuphoria Therapeutics rises on $15 mln milestone payment from Merck - TradingView
Neuphoria Therapeutics shares surge on $15M Merck payment - MSN
Neuphoria receives $15M milestone payment from Merck - MSN
Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market - Nasdaq
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com - Investing.com Australia
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going - MSN
Neuphoria Therapeutics Takes the Biotech Spotlight: U.S. Relocation and Nasdaq Debut Promise Game-Changing Opportunities - Jomfruland.net
Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Given New $21.00 Price Target at HC Wainwright - Armenian Reporter
Brokers Set Expectations for NEUP Q2 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock - Defense World
FY2027 Earnings Estimate for NEUP Issued By HC Wainwright - Defense World
Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday - MSN
10 Firms Defy Market Pessimism - Insider Monkey
Stock market news: Nvni Group +254.36%, Allurion Technologies +153.92% among top gainers during mid day trading - Business Upturn
Stock market news: Neuphoria Therapeutics and Nvni Group saw surge of 134.96% and 245.64% concurrently during mid day trading - Business Upturn
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com India
Neuphoria Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Australia
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session - Marketscreener.com
Bionomics Limited announced that it expects to receive $70 million in funding - Marketscreener.com
Bionomics Limited to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Marketscreener.com
Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - Marketscreener.com
NEUP (Neuphoria Therapeutics) Cash From Other Investing Act - GuruFocus.com
NEUP (Neuphoria Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Neuphoria Therapeutics Inc.NEUPStock Price Today - Zacks Investment Research
We're Keeping An Eye On Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Rate - Yahoo Finance
Bionomics Strategic Shift with Neuphoria Redomiciliation - Yahoo Finance
Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation - MarketWatch
Big Moves in Biotech! Neuphoria's Bold Transformation Unveiled! - Jomfruland.net
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - GlobeNewswire
Bionomics Secures Major Court Approval for Strategic US Market Shift, Sets December Trading Timeline - StockTitan
Results of Scheme Meeting - The Manila Times
Bionomics Limited (BNOX) Quarterly 10-Q Report - Quartz
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - GlobeNewswire
Bionomics CEO believes company has ‘significant, unrealized value’ - Yahoo Finance
Apeiron entities sell Bionomics shares worth $82,526 - Investing.com
Bionomics Limited announces intention to re-domicile to the United States - StockTitan
Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder - Marketscreener.com
Bionomics to Present at Biotech Showcase™ 2024 - Marketscreener.com
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms - Marketscreener.com
BNOXBionomics Limited American Depository Shares Latest Stock News & Market Updates - StockTitan
Neuphoria Therapeutics Inc (NEUP) 재무 분석
Neuphoria Therapeutics Inc (NEUP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.33%
2.00%
자본화:
|
볼륨(24시간):